ImmunityBio, Inc. (IBRX) dropped 8.62% due to negative sentiment and poor earnings

From Yahoo Finance: 2025-05-21 20:31:00

On Wednesday, 10 firms, including ImmunityBio, Inc. (IBRX), saw significant losses due to negative sentiment from government policies and poor earnings. The Dow Jones fell by 1.91%, the S&P 500 by 1.61%, and the Nasdaq by 1.41%. IBRX dropped by 8.62% to $2.65 per share, following negative comments from market experts.

Jim Cramer criticized IBRX on Mad Money, stating it was “not a great stock.” However, Piper Sandler upgraded IBRX to “overweight,” citing its promising Anktiva, t-haNK, and M-ceNK cell therapies and DNA vaccines. Despite ranking 6th in the list of firms in the red, AI stocks like IBRX offer potential but may have higher returns in a shorter timeframe.



Read more at Yahoo Finance: Why ImmunityBio, Inc. (IBRX) Crashed Today